Quest Diagnostics Surges with 100% Sensitive Haystack MRD Test & AI Lab Upgrade
Quest Diagnostics’ 2026 stock outlook shows strong YTD gains, AI‑powered lab tech, and a validated liquid‑biopsy test that could boost precision oncology revenue.
3 minutes to read

